Zacks Investment Research upgraded shares of HARVARD BIOSCI (HBIO) from NEUTRAL to OUTPERFORM on October 28, 2014, with a target price of $5.20.
HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on HARVARD BIOSCI (HBIO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment